## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Takehiko NAKA et al.

Title:

BENZIMIDAZOLE DERIVATIVES, THEIR

PRODUCTION AND USE

Prior Appl. No.:

10/046,189

Prior Filing Date:

January 16, 2002

Examiner:

Unassigned

Art Unit:

1626

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR 1.56

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/046,189, filed January 16, 2002. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

## RELEVANCE OF EACH DOCUMENT

Applicants submit herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in priority applications Serial Nos. 09/817,231; 09/376,494, and 08/924,9191. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified priority applications.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or

Tight 19 Mails

Stephen B. Maebius

Registration No. 35,264

even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

July 7, 2003

FOLEY & LARDNER

Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

Telephone: (2

(202) 672-5300

Facsimile:

(202) 672-5399

002,1032934.1

MODIFIED PTO/SB/08 (08-00

Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	Prior Appl. No. 10/046,189	
<u>'</u>	STATEMENT BY	APPLI	CANT	Filing Date	Prior FilingDate: January 16, 2002	
	Data Subm	ittod:		First Named Inv ntor	Takehiko Naka	
Date Submitted:(use as many sheets as necessary)				Group Art Unit	Unassigned	
				Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	087147-0486	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	A1	4,562,896		Schevrel et al.	07/1995	
	A2	4,764,623		Kees	08/1988	**
	A3	4,775,679		Chang	06/1988	
	A4	4,880,804		Carini et al	11/1989	
	A5	5,864,043		Narr et al.	01/1999	
	A6	4,663,339		Kisida et al.	05/1987	
	A7	4,612,323		Kisida et al.	09/1986	

			30	F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Fo Office <sup>3</sup>	reign Patent [ Number <sup>4</sup>	Document Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A8	EP	028833		Takeda Yakuhin Kogyo Kabushiki Kaisha	5/20/1981		
. **	A9	EP	028834		Takeda Yakuhin Kogyo Kabushiki Kaisha	5/20/1981		
	A10	EP	245637		Warner-Lambert Company	11/19/1987		
	A11	EP	023310		Eder, Franz X, Prof. Dr.	2/4/1981		
	A12	EP	0291969		E.I. Du Pont De Numours and Company	11/23/1988	*	
	A13	EP	0323847		E.I. Du Pont De Numours and Company	7/12/1989		
	A14	EP	0392317		Dr. Karl Thomae GmbH	10/17/1990		
	A15	EP	0400835		Merck & Co., Inc.	12/5/1990		
	A16	EP	0420237		Eisai Co., Ltd.	4/3/1991		
	A17	EP	0399732		Imperial Chemical Industries, Inc.	11/28/1990		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т6		
	A18	NODA et al., "Inhibitionof Rabbit Aortic Angiotensin II (All) Receptor by CU-11974, a new Nonpeptide All Antagonist," <i>Biochen Pharm.</i> , 1993, pgs. 311-318, Vol. 46, No. 2			

Examiner	Date	
Signature	Considered	
<u> </u>		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.